Clinigen, the global speciality pharmaceutical services group, today announced that Equity Pharmaceuticals, part of the Clinigen Group, has entered into a new collaboration with Servier, an ...

This Human Rights Day, DKMS highlights the urgent need for stem cell transplants for South African children battling rare ...

This Human Rights Day, DKMS highlights the urgent need for stem cell transplants for South African children battling rare ...

An indigenously developed gene therapy for specific blood cancers has shown a 73 per cent response rate among patients in ...

A new study published in The Lancet Haematology journal says that an indigenously developed gene therapy for certain blood ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...

Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) ...

Peacefully at rest on Wednesday 12th March 2025 at St. Ann's Hospice, Heald Green, Stockport, after an illness bravely borne, ...

An indigenously developed CAR T-cell gene therapy has achieved a 73% response rate for certain blood cancers in India. The ...